Stocks and Investing
Stocks and Investing
Fri, March 15, 2024
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
[ Fri, Mar 15th 2024
] - WOPRAI
Derek Archila Maintained (ASND) at Buy with Increased Target to $260 on, Mar 15th, 2024
Derek Archila of Wells Fargo, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $196 to $260 on, Mar 15th, 2024.
Derek has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 0 agree with Derek's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Derek
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $225 on, Thursday, February 8th, 2024
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $182 on, Thursday, February 8th, 2024
- Li Watsek of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $173 on, Tuesday, February 6th, 2024
- Kelly Shi of "Jefferies" Initiated at Strong Buy and Held Target at $150 on, Wednesday, December 20th, 2023
Contributing Sources